Skip to main content

ACAM2000 FDA Approval History

FDA Approved: Yes (First approved August 31, 2007)
Brand name: ACAM2000
Generic name: Smallpox (Vaccinia) Vaccine, Live
Company: Emergent BioSolutions Inc.
Treatment for: Smallpox Prophylaxis

ACAM2000 is live vaccinia virus smallpox vaccine intended for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. ACAM2000 is the first biodefense vaccine to be approved as part of the US response to the 2001 bioterrorism attacks.

Development timeline for ACAM2000

Sep  4, 2007Approval FDA Approves ACAM2000 Vaccine for Protection Against Smallpox

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.